Previous 10 | Next 10 |
2024-01-17 21:22:40 ET Summary Shares of Oxford Nanopore declined by 33% after slower than expected growth in the second half of 2023. Positive outlook on the company, but profitability not expected until 2026. Challenging market with slow adoption of new technology, but new p...
COSMOS study shows Guardant Reveal™ blood test highly predictive for disease recurrence in patients with early-stage colon cancer without need for tissue specimen Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS s...
2024-01-08 14:48:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2023 was dominated by the Magnificent Seven stocks, which has left investors wondering how much higher mega-cap stocks can go. Investors worry that growth is nearing a peak or perhaps reversing...
2024-01-08 13:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 12:28:24 ET More on Guardant Health Guardant Health: Vast Market Opportunity, Challenging Valuation Guardant Health, Inc. (GH) Q3 2023 Earnings Call Transcript Guardant Health, Inc. 2023 Q3 - Results - Earnings Call Presentation It's JPM time! Whic...
Full year revenue growth of 25% driven by clinical volume growth of 39% Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023. Full year 2023 preliminary unaudi...
2024-01-08 05:52:00 ET Cathie Wood crushed it in 2023. Her flagship Ark Innovation ETF (NYSEMKT: ARKK) soared nearly 67%. The Ark Next Generation Internet ETF (NYSEMKT: ARKW) performed even better with an impressive 97% gain. If analysts are right, Wood could have some b...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screenin...
2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...
2024-01-02 16:55:53 ET Gainers: Bloomin' Brands ( BLMN ) +6% . Arcutis Biotherapeutics ( ARQT ) +6% . Stronghold Digital Mining ( SDIG ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Guardant Health ( GH ) +3% . Losers: ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-11 09:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highligh...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...